Solasia Pharma K.K. (4597.T)
JPY 32.0
(-5.88%)
JPY 32.0
(-5.88%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -668 Million JPY | 12.79% |
| 2022 | -766 Million JPY | -21.59% |
| 2021 | -630 Million JPY | 66.91% |
| 2020 | -1.9 Billion JPY | 52.96% |
| 2019 | -4.04 Billion JPY | -0.05% |
| 2018 | -4.04 Billion JPY | -20.05% |
| 2017 | -3.37 Billion JPY | -224.37% |
| 2016 | -1.03 Billion JPY | -235.34% |
| 2015 | 767.7 Million JPY | -6.4% |
| 2014 | 820.19 Million JPY | 1378.15% |
| 2013 | 55.48 Million JPY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -898 Million JPY | -17.39% |
| 2024 Q1 | -765 Million JPY | -14.52% |
| 2023 Q4 | -668 Million JPY | -48.12% |
| 2023 FY | -668 Million JPY | 12.79% |
| 2023 Q1 | -926 Million JPY | -20.89% |
| 2023 Q2 | -375 Million JPY | 59.5% |
| 2023 Q3 | -451 Million JPY | -20.27% |
| 2022 Q1 | -717 Million JPY | -13.81% |
| 2022 Q4 | -766 Million JPY | 56.5% |
| 2022 Q3 | -1.76 Billion JPY | -93.3% |
| 2022 Q2 | -911 Million JPY | -27.06% |
| 2022 FY | -766 Million JPY | -21.59% |
| 2021 Q2 | -1.68 Billion JPY | 20.19% |
| 2021 Q4 | -630 Million JPY | 43.19% |
| 2021 Q3 | -1.1 Billion JPY | 34.14% |
| 2021 FY | -630 Million JPY | 66.91% |
| 2021 Q1 | -2.11 Billion JPY | -10.82% |
| 2020 FY | -1.9 Billion JPY | 52.96% |
| 2020 Q4 | -1.9 Billion JPY | -0.21% |
| 2020 Q3 | -1.9 Billion JPY | 18.56% |
| 2020 Q2 | -2.33 Billion JPY | 29.02% |
| 2020 Q1 | -3.28 Billion JPY | 18.8% |
| 2019 Q4 | -4.04 Billion JPY | -115.55% |
| 2019 FY | -4.04 Billion JPY | -0.05% |
| 2019 Q1 | -2.68 Billion JPY | 33.74% |
| 2019 Q3 | -1.87 Billion JPY | 23.63% |
| 2019 Q2 | -2.45 Billion JPY | 8.28% |
| 2018 Q3 | -4.64 Billion JPY | -124.49% |
| 2018 Q2 | -2.07 Billion JPY | 25.32% |
| 2018 Q1 | -2.77 Billion JPY | 17.75% |
| 2018 FY | -4.04 Billion JPY | -20.05% |
| 2018 Q4 | -4.04 Billion JPY | 12.93% |
| 2017 Q3 | -3.89 Billion JPY | 4.05% |
| 2017 Q2 | -4.06 Billion JPY | -1.92% |
| 2017 Q1 | -3.98 Billion JPY | -283.62% |
| 2017 Q4 | -3.37 Billion JPY | 13.54% |
| 2017 FY | -3.37 Billion JPY | -224.37% |
| 2016 Q4 | -1.03 Billion JPY | -155.3% |
| 2016 Q3 | 1.87 Billion JPY | 0.0% |
| 2016 FY | -1.03 Billion JPY | -235.34% |
| 2015 FY | 767.7 Million JPY | -6.4% |
| 2015 Q4 | 767.7 Million JPY | 0.0% |
| 2014 FY | 820.19 Million JPY | 1378.15% |
| 2013 FY | 55.48 Million JPY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 1.22 Billion JPY | 154.531% |
| Takeda Pharmaceutical Company Limited | 4385.95 Billion JPY | 100.015% |
| Sumitomo Pharma Co., Ltd. | 389.83 Billion JPY | 100.171% |
| Shionogi & Co., Ltd. | -346.47 Billion JPY | 99.807% |
| Wakamoto Pharmaceutical Co.,Ltd. | -3.56 Billion JPY | 81.258% |
| Nippon Shinyaku Co., Ltd. | -42.15 Billion JPY | 98.415% |
| Kaken Pharmaceutical Co., Ltd. | -61.47 Billion JPY | 98.913% |
| Eisai Co., Ltd. | -97.93 Billion JPY | 99.318% |
| Morishita Jintan Co., Ltd. | -667 Million JPY | -0.15% |
| Hisamitsu Pharmaceutical Co., Inc. | -51.82 Billion JPY | 98.711% |
| Mochida Pharmaceutical Co., Ltd. | -32.92 Billion JPY | 97.971% |
| Fuso Pharmaceutical Industries,Ltd. | 7.6 Billion JPY | 108.787% |
| Nippon Chemiphar Co., Ltd. | 7.78 Billion JPY | 108.585% |
| Tsumura & Co. | 1.61 Billion JPY | 141.362% |
| Kissei Pharmaceutical Co., Ltd. | -44.16 Billion JPY | 98.487% |
| Torii Pharmaceutical Co., Ltd. | -34.43 Billion JPY | 98.06% |
| Towa Pharmaceutical Co., Ltd. | 172.7 Billion JPY | 100.387% |
| Fuji Pharma Co., Ltd. | 26.62 Billion JPY | 102.509% |
| Zeria Pharmaceutical Co., Ltd. | 28.98 Billion JPY | 102.305% |
| KYORIN Holdings, Inc. | 7.06 Billion JPY | 109.462% |
| Taiko Pharmaceutical Co.,Ltd. | 704 Million JPY | 194.886% |
| Daito Pharmaceutical Co.,Ltd. | 5.99 Billion JPY | 111.148% |
| SymBio Pharmaceuticals Limited | -6.51 Billion JPY | 89.75% |
| MedRx Co., Ltd | -1.72 Billion JPY | 61.163% |
| Mizuho Medy Co.,Ltd. | -8.71 Billion JPY | 92.336% |
| Modalis Therapeutics Corporation | -1.47 Billion JPY | 54.587% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | -7.25 Billion JPY | 90.79% |
| Sawai Group Holdings Co., Ltd. | 56.52 Billion JPY | 101.182% |
| Cyfuse Biomedical K.K. | -2.96 Billion JPY | 77.438% |
| Toho Holdings Co., Ltd. | -98.42 Billion JPY | 99.321% |
| Koa Shoji Holdings Co.,Ltd. | -11.12 Billion JPY | 93.998% |